Literature DB >> 2551767

High plasma pancreastatinlike immunoreactivity in a patient with malignant insulinoma.

K Tateishi1, A Funakoshi, A Jimi, S Funakoshi, H Tamamura, H Yajima, Y Matsuoka.   

Abstract

High levels of pancreastatinlike immunoreactivity were detected in the plasma (2.9 pmol/ml, greater than 200-fold the normal level), pancreas (2.9 nmol/g wet wt, greater than 450-fold the normal level), and liver (1.6 nmol/g wet wt) of a patient with pancreatic insulinoma with metastasis to the liver by a sensitive and specific radioimmunoassay for human pancreastatin. Antiserum was produced against the C-terminal fragment of human pancreastatin-(24-52), which was synthesized according to the sequence of human chromogranin A corresponding to that of pancreastatin. With the antiserum, intense immunocytochemical staining was detected in the tumors. Sephadex G-50 gel filtration showed that the tumors and plasma contained two molecular forms of pancreastatinlike immunoreactivity--a molecular form coeluted with synthetic human pancreastatin-52 and a larger molecular form (Mr approximately 12,000-15,000). The smaller form eluted in the same position as synthetic human pancreastatin-52 on reverse-phase high-performance liquid chromatography.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551767     DOI: 10.1016/0016-5085(89)91705-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

1.  Plasma pancreastatin responses after intrajejunal infusion of liquid meal in patients with chronic pancreatitis.

Authors:  A Funakoshi; K Tateishi; H Shinozaki; K Miyasaka; T Ito; H Wakasugi
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

2.  Direct, concentration-dependent inhibition by taurocholate of pancreatic exocrine secretion and CCK release in conscious rats.

Authors:  H Tomita; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

3.  Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.

Authors:  N Sazaki; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

4.  Immunohistochemical Localization of Chromostatin and Pancreastatin, Chromogranin A-Derived Bioactive Peptides, in Normal and Neoplastic Neuroendocrine Tissues.

Authors:  Noriko Kimura; Akihiro Funakoshi; Dominique Aunis; Kayoko Tateishi; Wakako Miura; Hiroshi Nagura
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.